EoPancreas: New Diabetes Patch Pump and CGM System in Development

FDA has granted "Breakthrough Device Designation" to South Korean company EoFlow, developing a tubeless patch-pump based Automated Insulin Delivery (AID) system.
FDA has granted Breakthrough Device Designation to South Korean company EoFlow, developing a tubeless patch-pump based Automated Insulin Delivery (AID) system.

Update November 2021

The Future of Closed-Loop Systems

December update on closed-loop systems

Savvy Updates, 1/9/22: Beta Bionics NEW CMO, EoFlow Patch Pump Submits to FDA, Fruits/Veggies App, How Ozempic/Wegovy Work, Drug Makers Raise Prices 2023, Happy Bob App

Medtronic nixes $738M deal for insulin patch pump maker EOFlow

Medical devices, smart drug delivery, wearables and technology for the treatment of Diabetes Mellitus - ScienceDirect

Diabetes Café (@Diabetesto) / X

Quarterly Update Diabetes Technology

Medical devices, smart drug delivery, wearables and technology for the treatment of Diabetes Mellitus - ScienceDirect